0001104659-23-005077.txt : 20230119 0001104659-23-005077.hdr.sgml : 20230119 20230119171725 ACCESSION NUMBER: 0001104659-23-005077 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 23538210 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 425 1 tm2227887d22_425.htm 425

 

Filed by Sesen Bio, Inc.

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-6(b)

under the Securities Exchange Act of 1934

 

Subject Company: Sesen Bio, Inc.

Commission File No.: 001-36296

 

On January 19, 2023, CARISMA Therapeutics Inc. published the following post on Twitter:

NEW: Sesen Bio $SESN files definitive proxy statement and mails letter to stockholders in connection with our pending merger. The merger is expected to close in the first quarter of 2023, subject to approval by Sesen Bio's stockholders. Impt Info here: [LINK TO PRESS RELEASE]

 

On January 19, 2023, CARISMA Therapeutics Inc. published the following post on LinkedIn:

We are excited to share that Sesen Bio filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with our pending merger. The pending merger is expected to close in the first quarter of 2023, subject to approval by Sesen Bio’s stockholders and other customary closing conditions. Also announced is the launch of a website providing additional information for stockholders.

 

Important Information Here: [LINK TO PRESS RELEASE]

 

On January 19, 2023, Steven Kelly, President and Chief Executive Officer of CARISMA Therapeutics Inc., published the following post on LinkedIn:

Exciting update regarding [tag] Carisma’s pending merger with [tag] Sesen Bio. With the definitive proxy materials being filed and the launch of a new website for stockholders, we’re one step closer to completing the merger in the first quarter of 2023. Learn more here: [LINK TO PRESS RELEASE]